RU2021134325A - Производные хинолина для лечения воспалительных заболеваний - Google Patents

Производные хинолина для лечения воспалительных заболеваний Download PDF

Info

Publication number
RU2021134325A
RU2021134325A RU2021134325A RU2021134325A RU2021134325A RU 2021134325 A RU2021134325 A RU 2021134325A RU 2021134325 A RU2021134325 A RU 2021134325A RU 2021134325 A RU2021134325 A RU 2021134325A RU 2021134325 A RU2021134325 A RU 2021134325A
Authority
RU
Russia
Prior art keywords
group
sample
mir
reference value
inflammatory disease
Prior art date
Application number
RU2021134325A
Other languages
English (en)
Inventor
Жамаль ТАЗИ
Ромен НАЖМАН
Флоренс МАЮТО
Дидье ШЕРРЕР
Карим ШЕБЛИ
Мишель АН
Original Assignee
Абивакс
Сентр Насьональ Де Ла Решерш Сьентифик
Институт Кюри
Юниверсите Де Монпелье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Абивакс, Сентр Насьональ Де Ла Решерш Сьентифик, Институт Кюри, Юниверсите Де Монпелье filed Critical Абивакс
Publication of RU2021134325A publication Critical patent/RU2021134325A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)

Claims (37)

1. Применение по меньшей мере одной миРНК in vitro или ex vivo, где указанная по меньшей мере одна миРНК представляет собой miR-124, в качестве биомаркера для скрининга производного хинолина и, в частности, соединения формулы (I), предположительно эффективного при лечении и/или профилактике воспалительного заболевания, причем формула (I) определена ниже
Figure 00000001
(I),
где
Z представляет собой C или N,
V представляет собой C или N,
Figure 00000002
означает ароматическое кольцо, где V представляет собой C или N, и, когда V представляет собой N, V находится в орто-, мета- или пара- положении относительно Z, т.е. образует, соответственно, пиридиновую, пиридазиновую, пиримидиновую или пиразиновую группу,
R независимо представляет собой атом водорода, метильную группу, метоксигруппу, трифторметильную группу, трифторметоксигруппу, аминогруппу, атом галогена и группу -O-P(=O)-(OR3)(OR4), и, в частности, атом фтора или хлора, трифторметоксигруппу и аминогруппу,
Q представляет собой N или O, при условии, что R'' отсутствует, когда Q представляет собой O,
R3 и R4 независимо представляют собой атом водорода, Li+, Na+, K+, N+(Ra)4 или бензильную группу,
Ra представляет собой атом водорода, (C1-C5)алкильную группу или (C3-C6)циклоалкильную группу,
n равно 1, 2 или 3,
n' равно 1, 2 или 3,
R' независимо представляет собой атом водорода, атом галогена и более конкретно атом фтора или хлора, аминогруппу, метильную группу, группу -O-P(=O)-(OR3)(OR4) или группу
Figure 00000003
, где A представляет собой O или NH, m равно 2 или 3, и X1 представляет собой O, CH2 или N-CH3, при условии, что, когда R' представляет собой такую группу, n' равно 1 или 2, и, когда n' равно 2, другая группа R' отличается от указанной группы, или альтернативно R' независимо представляет собой атом водорода, атом галогена, и более конкретно атом фтора или хлора, метильную группу или группу
Figure 00000003
, где A представляет собой O или NH, m равно 2, и X1 представляет собой O, CH2 или N-CH3, при условии, что, когда R' представляет собой такую группу, n' равно 1 или 2, и, когда n' равно 2, другая группа R' отличается от указанной группы,
R'' представляет собой атом водорода, (C1-C4)алкильную группу или группу
Figure 00000004
, где m равно 2 или 3, и X1 представляет собой O, CH2 или N-CH3,
или любой из его фармацевтически приемлемых солей.
2. Применение in vitro или ex vivo по п. 1, где Q представляет собой N.
3. Применение in vitro или ex vivo по п. 1 или 2, где соединение выбрано из
Figure 00000005
(Ia),
Figure 00000006
(Ib) и
Figure 00000007
(Ic),
где R, R', R'', n и n' являются такими, как определено в п. 1 или 2.
4. Способ скрининга in vitro или ex vivo производного хинолина и, в частности, соединения формулы (I), как определено в любом из пп. 1-3, предположительно эффективного при лечении и/или профилактике воспалительного заболевания, включающий по меньшей мере стадию, на которой:
a) обеспечивают эукариотическую клетку,
b) приводят указанную клетку в контакт с производным хинолина и, в частности, с соединением формулы (I).
c) определяют экспрессию miR-124 в указанной клетке, и
d) выбирают соединение-кандидат, предположительно эффективное при лечении и/или профилактике воспалительного заболевания, когда уровень экспрессии miR-124, определенный на стадии c), повышен относительно эталонного значения.
5. Способ по п. 4, где указанная эукариотическая клетка представляет собой мононуклеарную клетку периферической крови (МКПК).
6. Способ оценки и наблюдения эффективности соединения формулы (I), как определено в любом из пп. 1-3, включающий определение присутствия или уровня экспрессии miR-124 в изолированном биологическом образце.
7. Способ по п. 6, где присутствие или уровень экспрессии miR-124 определяют в эукариотической клетке из биологического образца и сравнивают с контрольным эталонным значением.
8. Способ по п. 6 или 7, где биологический образец выбран из образца крови, плазмы, сыворотки крови, слюны, интерстициальной жидкости, мочи; образца клеток, такого как культура клеток, линия клеток, линия стволовых клеток или образца, содержащего мононуклеарные клетки периферической крови (МКПК), образца биопсии ткани, такого как ткань полости рта, ткань желудочно-кишечного тракта, кожа, слизистая оболочка полости рта, либо множество образцов из клинического исследования; указанный образец представляет собой неочищенный образец или очищенный до различных степеней перед хранением, обработкой или определением.
9. Способ по п. 7 или 8, где контрольное эталонное значение получено из изолированного биологического образца, полученного от индивида или группы индивидов, для которых известно, что они не страдают воспалительным заболеванием, и/или не получающих лечение, эффективность которого необходимо определять или подвергать мониторингу; или, альтернативно, контрольное эталонное значение получено из изолированного биологического образца, полученного у пациента, страдающего воспалительным заболеванием и получающего лечение, эффективность которого необходимо определять или подвергать мониторингу, где изолированный биологический образец получен у пациента перед проведением лечения.
10. Способ по любому из пп. 6-9, где присутствие и/или уровень экспрессии miR-124 в образце оценивают с использованием методов анализа или матричных тест-систем нуклеиновых кислот, таких как Нозерн-блоттинг и методы, основанные на полимеразной цепной реакции (ПЦР).
11. Способ по любому из пп. 6-10, при котором применяется способ обнаружения и количественного определения нуклеиновых кислот, который может представлять собой способ, основанный на гибридизации, причем указанные способы, основанные на гибридизации, включают методы ПЦР и количественной ПЦР (кОТ-ПЦР или к-ПЦР) или методы с использованием обратной транскриптазы/полимеразы.
12. Способ по п. 11, где способ включает стадию секвенирования или объединен с ней.
13. Способ по любому из пп. 6-12, который включает (i) стадию экстракции клеточных мРНК, (ii) стадию обратной транскрипции мРНК в ДНК с помощью обратной транскриптазы и (iii) стадию амплификации ДНК с ДНК, полученной на предшествующей стадии.
14. Способ по любому из пп. 6-13, где модулирование присутствия или уровня экспрессии miR-124 относительно контрольного образца, такого как контрольное эталонное значение, полученное у здорового донора, является показателем воспалительного заболевания.
15. Способ по п. 14, где уменьшенное или подавленное присутствие или сниженный уровень экспрессии miR-124 относительно контрольного эталонного значения, такого как контрольное эталонное значение, полученное у здорового донора, является показателем воспалительного заболевания.
RU2021134325A 2014-07-17 2015-07-17 Производные хинолина для лечения воспалительных заболеваний RU2021134325A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306164.6 2014-07-17
EP14306164.6A EP2974729A1 (en) 2014-07-17 2014-07-17 Quinoline derivatives for use in the treatment of inflammatory diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2017101407A Division RU2760686C2 (ru) 2014-07-17 2015-07-17 Производные хинолина для лечения воспалительных заболеваний

Publications (1)

Publication Number Publication Date
RU2021134325A true RU2021134325A (ru) 2021-12-02

Family

ID=51220531

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2021134325A RU2021134325A (ru) 2014-07-17 2015-07-17 Производные хинолина для лечения воспалительных заболеваний
RU2017101407A RU2760686C2 (ru) 2014-07-17 2015-07-17 Производные хинолина для лечения воспалительных заболеваний

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017101407A RU2760686C2 (ru) 2014-07-17 2015-07-17 Производные хинолина для лечения воспалительных заболеваний

Country Status (20)

Country Link
US (5) US10435370B2 (ru)
EP (3) EP2974729A1 (ru)
JP (3) JP6884690B2 (ru)
KR (2) KR20230078827A (ru)
CN (5) CN117568459A (ru)
AU (4) AU2015289033A1 (ru)
CA (2) CA3166018A1 (ru)
CU (2) CU24565B1 (ru)
DK (1) DK3169328T3 (ru)
ES (1) ES2914066T3 (ru)
HR (1) HRP20220598T1 (ru)
HU (1) HUE058713T2 (ru)
LT (1) LT3169328T (ru)
MX (2) MX2017000533A (ru)
PL (1) PL3169328T3 (ru)
PT (1) PT3169328T (ru)
RS (1) RS63231B1 (ru)
RU (2) RU2021134325A (ru)
SI (1) SI3169328T1 (ru)
WO (1) WO2016009065A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3669874A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
KR102399037B1 (ko) * 2020-01-06 2022-05-17 성균관대학교산학협력단 아민화된 아진의 신규한 제조방법
CN114073700B (zh) * 2020-08-19 2023-08-01 中山大学中山眼科中心 Iox1在自身免疫性疾病的预防和/或治疗中的应用
WO2022247920A1 (zh) 2021-05-27 2022-12-01 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
TW202333698A (zh) * 2022-01-24 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 喹啉胺類化合物、其製備方法及其在醫藥上的應用
EP4215196A1 (en) * 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (ru) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
JPS5272821A (en) * 1975-12-15 1977-06-17 Mitsubishi Petrochem Co Ltd Herbicide
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
JPS5651454A (en) * 1979-10-01 1981-05-09 Nissan Chem Ind Ltd Hydroquinone derivative and its preparation
US4738710A (en) 1979-11-19 1988-04-19 Ici Australia Limited Herbicidal alkane carboxylic acid derivatives
US4425343A (en) 1980-10-24 1984-01-10 Nissan Chemical Industries, Ltd. Benzoazine ether or thioether linkage containing urea compounds, process for producing same and insecticides containing said compounds
JPS5772968A (en) 1980-10-24 1982-05-07 Nissan Chem Ind Ltd Aniline derivative and its preparation
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
WO2000059875A2 (en) 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (ru) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Производные бензоимидазола, которые применяются как антипролиферативное средство, фармацевтическая композиция на их основании
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
AU2002303078B2 (en) 2001-01-22 2007-08-30 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US7425564B2 (en) 2001-06-22 2008-09-16 Kirin Beer Kabushiki Kaisha Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
US6498254B1 (en) 2001-10-29 2002-12-24 Uniroyal Chemical Company, Inc. Antiretroviral compounds and compositions
ES2355472T3 (es) 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
BR0312999A (pt) 2002-07-19 2005-06-07 Memory Pharm Corp Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
AU2004285811B2 (en) * 2003-10-31 2008-06-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
EP1689387B1 (en) 2003-11-19 2011-09-14 Array Biopharma, Inc. Bicyclic inhibitors of mek and methods of synthesis thereof
MXPA06007242A (es) * 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
WO2006060318A2 (en) 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
CA2600869A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CN101213260A (zh) 2005-06-29 2008-07-02 株式会社Adeka 树脂添加剂组合物和其树脂组合物
WO2007042899A2 (en) 2005-10-10 2007-04-19 Council Of Scientific And Industrial Research Human microrna targets in hiv genome and a method of identification thereof
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
CN101589026B (zh) 2006-06-22 2013-10-16 普拉纳生物技术有限公司 治疗脑神经胶质瘤的方法
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
BRPI0718510A2 (pt) 2006-09-21 2013-11-19 Piramal Life Sciences Ltd Derivados de 3-amino piridina para o tratamento de desordens metabólicas
AU2008206045A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
NZ579834A (en) 2007-03-23 2012-03-30 Amgen Inc Heterocyclic compounds as selective inhibitors of PI3K activity
JP5603233B2 (ja) 2007-05-17 2014-10-08 エルジー・ケム・リミテッド 新規なアントラセン誘導体およびそれを用いた有機電子素子
WO2008153692A2 (en) 2007-05-22 2008-12-18 The Brigham And Women's Hospital, Inc. Microrna expression profiling of cerebrospinal fluid
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
MX2010001576A (es) 2007-08-15 2010-09-14 Memory Pharm Corp Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
WO2009029617A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
EP2235213A2 (en) 2007-12-20 2010-10-06 Celgene Corporation Use of micro-rna as a biomarker of immunomodulatory drug activity
KR100974562B1 (ko) 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
JP2009174368A (ja) 2008-01-23 2009-08-06 Toyota Motor Corp 内燃機関の排気浄化装置
CA2717453A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinolines
WO2009132273A2 (en) 2008-04-25 2009-10-29 Merck & Co., Inc. Microrna biomarkers of tissue injury
US20160041153A1 (en) 2008-11-12 2016-02-11 Kirk Brown Biomarker compositions and markers
CA2753657A1 (en) 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
EP2427434B1 (en) 2009-05-05 2017-05-31 Boehringer Ingelheim International GmbH Process for preparing bromo-substituted quinolines
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN106928194B (zh) * 2009-06-12 2019-11-12 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
US10253020B2 (en) * 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
MX2019008390A (es) 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
CN102711793A (zh) * 2009-10-09 2012-10-03 悉生物有限公司 伴侣蛋白10变异体
US8648017B2 (en) 2009-11-04 2014-02-11 Diamir, Llc Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
UA111272C2 (uk) * 2010-06-23 2016-04-11 Ханмі Сайєнс Ко., Лтд. Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
WO2012118988A1 (en) 2011-03-01 2012-09-07 The Scripps Research Institute Direct reprogramming of human fibroblasts to functional neurons under defined conditions
SI2756099T1 (sl) 2011-09-15 2017-11-30 Self-Screen B.V. Postopek za detekcijo HPV-induciranega raka materničnega vratu
JP2016504268A (ja) 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
RU2681943C9 (ru) * 2013-07-05 2019-05-16 Абивакс Соединения, полезные для лечения заболеваний, вызванных ретровирусами
WO2015131019A1 (en) * 2014-02-28 2015-09-03 The Texas A&M University System Compositions and methods for inhibition of mycobacteria
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
ES2899926T3 (es) 2016-03-18 2022-03-15 Prosynergia S A R L Procedimiento para preparar derivados de quinolin-2-il-fenilamina y sus sales

Also Published As

Publication number Publication date
EP3169328B1 (en) 2022-03-09
US20210087145A1 (en) 2021-03-25
US20170204063A1 (en) 2017-07-20
BR112017000682A2 (pt) 2018-01-09
AU2015289033A1 (en) 2017-02-02
SI3169328T1 (sl) 2022-11-30
JP2023052265A (ja) 2023-04-11
CU24565B1 (es) 2022-01-13
CN107207463B (zh) 2023-10-24
DK3169328T3 (da) 2022-05-30
PL3169328T3 (pl) 2022-07-11
US20220315535A1 (en) 2022-10-06
EP2974729A1 (en) 2016-01-20
CN117568459A (zh) 2024-02-20
JP2017522313A (ja) 2017-08-10
WO2016009065A2 (en) 2016-01-21
US10435370B2 (en) 2019-10-08
KR20170032361A (ko) 2017-03-22
CA2954951A1 (en) 2016-01-21
MX2017000533A (es) 2017-04-27
RU2017101407A3 (ru) 2019-01-17
RS63231B1 (sr) 2022-06-30
AU2020200333A1 (en) 2020-02-06
US10981874B2 (en) 2021-04-20
LT3169328T (lt) 2022-06-10
JP2021038219A (ja) 2021-03-11
CA2954951C (en) 2022-10-18
PT3169328T (pt) 2022-05-27
EP3169328A2 (en) 2017-05-24
CN117281805A (zh) 2023-12-26
CN117379426A (zh) 2024-01-12
MX2021006754A (es) 2021-07-15
RU2760686C2 (ru) 2021-11-29
US20210047273A1 (en) 2021-02-18
AU2023202386A1 (en) 2023-06-29
CU20170004A7 (es) 2017-06-05
US11649211B2 (en) 2023-05-16
HRP20220598T1 (hr) 2022-06-24
ES2914066T3 (es) 2022-06-07
CU24459B1 (es) 2019-12-03
KR102537958B1 (ko) 2023-05-30
EP3998070A1 (en) 2022-05-18
AU2020200333B2 (en) 2021-01-21
CN117205212A (zh) 2023-12-12
AU2021201960B2 (en) 2023-02-23
US20190382347A1 (en) 2019-12-19
JP7208957B2 (ja) 2023-01-19
KR20230078827A (ko) 2023-06-02
RU2017101407A (ru) 2018-08-17
CU20190043A7 (es) 2019-12-03
HUE058713T2 (hu) 2022-09-28
AU2021201960A1 (en) 2021-04-29
CA3166018A1 (en) 2016-01-21
JP6884690B2 (ja) 2021-06-09
US11649210B2 (en) 2023-05-16
WO2016009065A3 (en) 2016-03-24
CN107207463A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
RU2021134325A (ru) Производные хинолина для лечения воспалительных заболеваний
JP2021038219A5 (ru)
Just et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers
EP2951315B1 (en) Non-invasive diagnostic method for diagnosing bladder cancer
JP6607568B2 (ja) バイオマーカーとしてのｍｉＲＮＡ−１２４
JP4206425B2 (ja) 大腸癌マーカー検出方法
JP2010536372A5 (ru)
KR20190057305A (ko) 자궁내막증에 대한 바이오마커로서의 microRNAs
KR102505827B1 (ko) 이식거부 및 면억억제 요법의 내성을 진단하기 위한 마이크로 리보핵산(miRNA)의 용도
US11814680B2 (en) Biomarkers for detecting senescent cells
JP2017184642A (ja) 認知症マーカー、それを用いた認知症の評価方法、評価試薬および評価キット
WO2014028862A1 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
JPWO2007018257A1 (ja) 大腸癌マーカー検出方法
WO2015121737A4 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
US20210301340A1 (en) Method of evaluating quality of body fluid specimen
JP2014532394A (ja) 尿の分析により腎臓マーカーを定量する方法
KR101381894B1 (ko) 위암의 림프절 전이 진단 마커로서의 혈청 ｍｉＲＮＡ
JP2019187413A (ja) ループス腎炎の検出またはそのリスクを予測する方法およびその応用
KR102505618B1 (ko) 신장이식 후 항체 매개성 거부반응의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도
US20150087549A1 (en) Methods of using tissue biomarkers for indication of progression from barretts esophagus to esophageal adenocarcinoma
JP2009112255A (ja) 皮膚のシミ形成を予測する皮膚検査方法
KR102545543B1 (ko) BK 바이러스 신병증의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도
JP2011004693A (ja) 精神疾患の診断方法（Ａｍｙ１ａ遺伝子）
JP2010187547A (ja) 精神疾患の診断方法
JPWO2008093530A1 (ja) 大腸癌病期検出方法